All In Biotech

Drug Trial Radar · NCT05774405

Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients

Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients: A Randomized Placebo-Controlled Study

Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 9,169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,169

Actual

Start

Jul 1, 2020

Primary completion

Jul 31, 2021

Study completion Jul 31, 2021

Sponsor

Lead sponsor
Istanbul University - CerrahpasaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Turkish Menopause and Osteoporosis Society; Karakoy Rotary Club; Rebul Pharmacy
First posted
Mar 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized placebo-controlled study is to investigate the short-term effects of transdermal estrogen therapy on postmenopausal women with COVID-19 disease. The main question\[s\] it aims to answer are: * the clinical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease * the biochemical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease All participants received favipiravir for a week according to the national guidelines published by the Health Ministry of Turkish Republic at that time. As an intervention, transdermal estradiol patch (7.8 mg patch/week) was applied for 14 days on the upper buttock of the patients in experimental arm. As a placebo, hydrogel patch (adhesive hydrogel patch/week) was applied to the female patients for 14 days. Researchers compared experimental and control groups to see if the impact of adding estrogen on the clinical course of Covid-19 disease

Conditions

  • COVID-19
  • Hormone Replacement Therapy

Interventions

  • Climara 0.1Mg/24Hr Transdermal SystemDrug

    Transdermal estradiol patch is used.

  • Hydrogel patchOther

    Adhesive Hydrogel patch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evidence of disease progression for mild casesTime frame: 15 days
  2. Evidence of disease progression for moderate and severe casesTime frame: 15 days
  3. Kidney function testsTime frame: 15 days
  4. PlateletTime frame: 15 days
  5. Markers of coagulationTime frame: 15 days
  6. Marker of inflammationTime frame: 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Istanbul University-Cerrahpasa

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.